BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For
information on access to our products, please call our customer service line at 1-800-469-0261.
When choosing this option please have the following information ready:
If you wish to be contacted by your local BDSI representative, call 1-800-469-0261 and select option 6.
Total 2021 Net Revenue expected in the range of $165 - $167 million , as compared to previous guidance of $162-$167 million BELBUCA 2021 Net Sales expected to be in the range of $147 - $148 million , as compared to previous guidance of $144-$148 million 2021 EBITDA expected to be in the $40 - $45Read more
RALEIGH, N.C. , Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that the U.S.Read more
Total Net Revenue of $41.1 Million , an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07 , EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral solution for acute migraine with potentialRead more